Drug Trial Radar · NCT04804514
Evaluation of the Safety and Tolerability of KH001 in Dentin Hypersensitivity Patients
Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jun 14, 2021
Primary completion
Mar 3, 2023
Study completion Mar 3, 2023
Sponsor
- Lead sponsor
- HysensBio Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2a study in dentin hypersensitivity patients to assess the safety, tolerability, efficacy and pharmacokinetics of single and multiple doses of KH001.
Conditions
- Dentin Sensitivity
Interventions
KH001Drug
The study drug is applied to teeth
PlaceboDrug
The placebo is applied to teeth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse events(AEs)Time frame: up to 22 days and 36 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Dental Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.